Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Feb 28;8(2):e019007.
doi: 10.1136/bmjopen-2017-019007.

Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im P act of R esidual Inflammation Detected via Imaging T E chniques, D rug Levels and Patient Characteristics on the Outcome of Dose Taper I ng of Adalimumab in C linical Remission Rheumatoid Ar T hritis (RA) patients (PREDICTRA)

Paul Emery  1   2 , Gerd R Burmester  3 , Esperanza Naredo  4 , Yijie Zhou  5 , Maja Hojnik  6 , Philip G Conaghan  1   2
Affiliations
Clinical Trial

Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im P act of R esidual Inflammation Detected via Imaging T E chniques, D rug Levels and Patient Characteristics on the Outcome of Dose Taper I ng of Adalimumab in C linical Remission Rheumatoid Ar T hritis (RA) patients (PREDICTRA)

Paul Emery et al. BMJ Open. .

Abstract

Introduction: The current American College of Rheumatology and European League Against Rheumatism treatment recommendations advise tapering biological disease-modifying antirheumatic drug (bDMARD) therapy in patients with rheumatoid arthritis (RA) who achieve stable clinical remission while receiving bDMARDs. However, not all patients maintain remission or low disease activity after tapering or discontinuation of bDMARDs. The aim of the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) study, or PREDICTRA, is to generate data on patient and disease characteristics that may predict the clinical course of a fixed dose-tapering regimen with the bDMARD adalimumab.

Methods and analysis: PREDICTRA is an ongoing, multicentre, phase IV, randomised, double-blind, parallel-group study of adalimumab dose tapering controlled by withdrawal in participants with RA who achieved stable clinical remission while receiving adalimumab. The study includes a screening period, a 4-week lead-in period with open-label adalimumab 40 mg every other week and a subsequent 36-week double-blind period during which participants are randomised 5:1 to adalimumab 40 mg every 3 weeks (taper arm) or placebo (withdrawal arm). The primary explanatory efficacy variables are lead-in baseline hand and wrist MRI-detected synovitis and bone marrow oedema scores, as well as a composite of both scores; the dependent variable is the occurrence of flare up to week 40. Additional efficacy variables, safety, pharmacokinetics, biomarkers and immunogenicity will also be assessed, and an ultrasound substudy will be conducted.

Ethics and dissemination: The study is conducted in accordance with the International Conference on Harmonisation guidelines, local laws and the ethical principles of the Declaration of Helsinki. All participants are required to sign a written informed consent statement before the start of any study procedures.

Trial registration number: EudraCT 2014-001114-26 and NCT02198651; Pre-results.

Keywords: adalimumab; discontinuation; rheumatoid arthritis; rheumatology; tapering; withdrawal.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PE has received research grants and/or consulting fees from AbbVie, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz and UCB. GRB has received research grants and/or consulting fees from AbbVie, Bristol-Myers Squibb, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz and UCB. EN has received speaker fees from AbbVie, Roche, Bristol-Myers Squibb, Pfizer, UCB, Lilly, Novartis, Janssen and Celgene GmbH and honoraria from AbbVie. YZ and MH are full-time employees of AbbVie and may hold AbbVie stock or stock options. PGC has received speakers’ bureau or consulting fees from AbbVie, Bristol- Myers Squibb, Lilly, Novartis, Pfizer and Roche.

Figures

Figure 1
Figure 1
Study design. *Flare at any time point; flare defined as either (1) DAS28(ESR) ≥2.6 with an increase in DAS28(ESR) by >0.6 or (2) an increase in DAS28(ESR) by ≥1.2 from dbBL irrespective of absolute DAS28(ESR) score. Participants who flare at any time during the randomised double-blind period will be switched to open-label ADA 40 mg eow and continue in the open-label rescue arm for 16 weeks up to a maximum study duration of 56 weeks. †If applicable. ADA, adalimumab; DAS28(CRP), Disease Activity Score based on 28 joints and C reactive protein; DAS28(ESR), Disease Activity Score based on 28 joints and erythrocyte sedimentation rate; dbBL, double-blind baseline; ew, every week; eow, every other week; e3w; every 3 weeks; F, flare; MTX, methotrexate; R, randomisation; RA, rheumatoid arthritis; sc, subcutaneously; US, ultrasound.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wolfe F, Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:1563–70. 10.1002/art.24724 - DOI - PubMed
    1. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18:S295–302. - PubMed
    1. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28–33. 10.1093/rheumatology/39.1.28 - DOI - PubMed
    1. Smolen JS, Breedveld FC, Burmester GR, et al. . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3–15. 10.1136/annrheumdis-2015-207524 - DOI - PMC - PubMed
    1. Aaltonen KJ, Virkki LM, Malmivaara A, et al. . Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275 10.1371/journal.pone.0030275 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data